| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.04T | 3.04T | 2.78T | 2.73T | 2.46T | 2.11T |
| Gross Profit | 967.15B | 958.26B | 815.97B | 773.78B | 769.77B | 680.71B |
| EBITDA | 396.57B | 389.80B | 218.49B | 120.65B | 366.89B | 287.39B |
| Net Income | 120.62B | 135.00B | 43.81B | -91.95B | 161.88B | 79.77B |
Balance Sheet | ||||||
| Total Assets | 3.96T | 4.02T | 3.66T | 3.45T | 3.35T | 2.92T |
| Cash, Cash Equivalents and Short-Term Investments | 384.01B | 393.47B | 338.11B | 251.18B | 244.64B | 221.78B |
| Total Debt | 1.22T | 1.20T | 955.56B | 974.75B | 777.22B | 663.78B |
| Total Liabilities | 2.09T | 2.10T | 1.81T | 1.76T | 1.63T | 1.42T |
| Stockholders Equity | 1.82T | 1.86T | 1.81T | 1.66T | 1.69T | 1.47T |
Cash Flow | ||||||
| Free Cash Flow | 80.95B | 99.81B | 123.35B | -81.35B | 13.56B | 103.38B |
| Operating Cash Flow | 276.59B | 301.49B | 295.30B | 90.80B | 183.27B | 253.68B |
| Investing Cash Flow | -322.01B | -381.15B | -142.60B | -213.58B | -221.02B | -157.75B |
| Financing Cash Flow | 96.63B | 144.57B | -94.33B | 111.78B | 42.32B | -95.87B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥1.64T | 13.74 | 7.48% | 3.15% | 3.55% | 95.65% | |
72 Outperform | ¥687.97B | 15.27 | 19.69% | 3.41% | 10.06% | 18.03% | |
71 Outperform | $697.83B | 17.27 | 4.79% | 4.55% | -1.21% | -27.21% | |
70 Outperform | $1.06T | 29.00 | 1.67% | 1.13% | -1.90% | -71.97% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | $703.12B | 8.29 | 8.79% | 2.64% | -1.64% | ― | |
54 Neutral | $1.10T | 10.09 | 1.09% | 3.97% | -11.50% | 25.86% |
Asahi Kasei Corporation is a diversified Japanese company operating in the chemicals, electronics, and healthcare sectors, known for its innovation and wide-ranging industrial applications. In its latest earnings report for the first and second quarters of fiscal 2025, Asahi Kasei reported a slight decline in net sales to ¥1,486,368 million, down 0.3% from the previous year, but saw a significant increase in net income attributable to owners of the parent, which rose by 10% to ¥66,266 million. The company also reported a comprehensive income of ¥71,515 million, a notable improvement from the previous year’s loss. Key financial metrics included a slight decrease in operating income to ¥107,454 million and an increase in ordinary income to ¥106,068 million. The company also highlighted a strong performance in extraordinary income, primarily driven by gains on sales of investment securities and shares of subsidiaries. Looking forward, Asahi Kasei has revised its fiscal 2025 forecast, projecting modest growth in net sales and operating income, with a continued focus on strategic investments and operational efficiencies to drive future growth.
Asahi Kasei Corp. announced its decision to acquire additional shares through its stock-based remuneration system to ensure sufficient shares for future grants to directors and executives. This move, involving a maximum acquisition cost of 2,520,000,000 yen for up to 1,825,800 shares, is part of the company’s strategy to maintain its remuneration framework, potentially impacting its financial strategy and shareholder value.
The most recent analyst rating on (JP:3407) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei reported stable operating income for the fiscal 2025 second quarter, with notable growth in its healthcare and domestic housing sectors, despite challenges in its materials segment. The company anticipates record-high operating income for the second consecutive year, driven by strong performance in pharmaceuticals and electronics, and plans to enhance shareholder returns through increased dividends and a share repurchase program.
The most recent analyst rating on (JP:3407) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei reported its consolidated financial results for the first and second quarters of fiscal 2025, showing a slight decline in net sales by 0.3% compared to the previous year. Despite this, the company experienced a significant increase in net income attributable to owners, rising by 10.0%. The company also revised its fiscal 2025 forecast, anticipating a modest growth in net sales and income. The elimination of six companies, including Asahi Kasei Medical Co., Ltd., from its consolidation scope, indicates a strategic shift in its business operations. The company maintained its cash dividend forecast, reflecting stability in shareholder returns.
The most recent analyst rating on (JP:3407) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei Homes, a subsidiary of Asahi Kasei Corp., is set to acquire a significant stake in R.C. Core Co., Ltd., marking a strategic move to enhance its offerings in the housing sector. This acquisition, which involves 14.01% of voting rights, is part of a broader capital and business alliance aimed at exploring new living concepts and diversifying lifestyle solutions, potentially impacting the market for naturalistic and unit homes.
The most recent analyst rating on (JP:3407) stock is a Hold with a Yen1272.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.